Skip to main content

Onglyza Plaintiffs Not So Happy...

Onglyza Plaintiffs Not So Happy...

Onglyza Plaintiffs Not So Happy...

Introduction

In spite of a list of side effects linked to Onglyza, there is only some success or positive movement at the plaintiff's end. Last year, 14 of them had their claims dismissed by a federal judge in California who granted the defendant AstraZeneca's motion for summary judgment despite a mandate by the FDA to have information about pancreatitis added to the warnings and precautions regarding Onglyza.

The 2009 FDA approved type 2 diabetes medication Onglyza, belongs to a class of DPP-4 inhibitors that control the blood sugar by helping the pancreas to produce more insulin after meals, thereby the amount of glucose produced by the liver is reduced. It was linked to a higher risk of pancreatic cancer and heart failure which became severe allegations faced by the defendants Bristol-Myers Squibb and AstraZeneca.

With our knowledge and expertise, we agree with the notion that there are good chances of an MDL formation as more cases are filed to join the existing lawsuits.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Talcum Powder Cancer Settlement Talks Begin Sept. 4

Categories: Talcum

Representatives of Johnson & Johnson (J&J) and attorneys for tens of thousands of plaintiffs involved in talcum powder lawsuits are scheduled to meet in September 2025 in an…

Tepezza Hearing Loss Trials Delayed Until Aug 2026

Categories: Tepezza

A series of Tepezza hearing loss lawsuits, which were expected to go before juries next year, will now be delayed. The U.S. District Judge overseeing the multidistrict…

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!